Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AIM ImmunoTech ( (AIM) ) has provided an update.
AIM ImmunoTech Inc. has implemented a Cash Conservation Plan where independent directors receive their compensation entirely in company stock instead of cash, aligning with the strategy to enhance shareholder value and support clinical progress. Executives have similarly adjusted their compensation, underlining their commitment to the company’s long-term goals and belief in Ampligen’s potential in critical medical fields.
For detailed information about AIM stock, go to TipRanks’ Stock Analysis page.